Shots:
- Tenaya has entered into a research collaboration with Alnylam to identify novel human genetic targets that could enable the development of disease-modifying therapies for cardiovascular (CV) diseases
- Under the collaboration, Tenaya will validate up to 15 gene targets, while Alnylam will lead all the development & commercialization of therapies arising from these validated targets
- As per the deal, Tenaya will receive ~$10M in upfront & cost reimbursements over the 2yrs. validation period, plus ~$1.13B in potential development & commercial milestones if the validated targets result in approved cardiovascular therapies
Ref: Globenewswire | Image: Tenaya & Alnylam | Press Release
Related News: Alnylam Pharmaceuticals’ Amvuttra Receives the EC’s Approval for ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
